Dogwood Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Dogwood Therapeutics, Inc. (DWTX) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $220.63 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-14
- Dogwood Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $32.80K.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $187.83K.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $302.90K.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $502.65K, a 15.74% decline year-over-year.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $608.29K.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$302.44K.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$223.46K.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $32.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $220.63K 10-Q · filed 2026-08-14 | $523.53K derived: sum of 3 quarters · filed 2026-08-14 | $1.03M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $187.83K 10-Q · filed 2026-05-15 | $490.73K derived: sum of 2 quarters · filed 2026-05-15 | $993.38K derived: sum of 3 quarters · filed 2026-05-15 | $979.47K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $302.90K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $805.55K derived: sum of 2 quarters · filed 2026-03-18 | $791.64K derived: sum of 3 quarters · filed 2026-08-14 | $608.29K 10-K · filed 2026-03-18 |
| 2025-09-30 | $502.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $488.74K derived: sum of 2 quarters · filed 2026-08-14 | $305.39K 10-Q · filed 2025-11-07 | -$629.27K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$13.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$197.26K 10-Q · filed 2026-08-14 | -$1.13M derived: sum of 3 quarters · filed 2026-08-14 | -$535.38K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$183.35K 10-Q · filed 2026-05-15 | -$1.12M derived: sum of 2 quarters · filed 2026-05-15 | -$521.47K derived: sum of 3 quarters · filed 2026-05-15 | -$612.48K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$934.66K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$338.12K derived: sum of 2 quarters · filed 2026-03-18 | -$429.13K derived: sum of 3 quarters · filed 2026-03-18 | -$302.44K 10-K · filed 2026-03-18 |
| 2024-09-30 | $596.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $505.53K derived: sum of 2 quarters · filed 2025-11-07 | $632.22K 10-Q · filed 2025-11-07 | |
| 2024-06-30 | -$91.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $35.68K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $126.69K 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | -$223.46K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |